Drug Profile
SB 01683
Alternative Names: SB-01683Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator Sprint Bioscience
- Class Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- Discontinued Triple negative breast cancer
Most Recent Events
- 09 Aug 2021 Discontinued - Preclinical for Triple negative Breast cancer in Sweden (unspecified route) (Sprint Bioscience pipeline, August 2021)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Sweden
- 01 Jun 2020 Sprint Bioscience receives notification of patent approval from European Patent Office for Vps34 inhibitors